12 Stocks Corporate Insiders are Abandoning - 2 of 12

 
 

Neurocrine Biosciences (NASDAQ:NBIX)

Dollar Amount of Shares Sold
$60,083,750.33
Number of Insider Stock Sales in the Last 180 Days
34
Volume of Shares Sold
452,178
Who Sold Shares
Darin Lippoldt (Insider), David W Boyer (Insider), Eiry Roberts (Insider), Eric Benevich (Insider), Gary A Lyons (Director), George J Morrow (Director), Ingrid Delaet (Insider), Jude Onyia (Insider), Kevin Charles Gorman (CEO), Kyle Gano (Insider), Leslie V Norwalk (Director), Matt Abernethy (CFO), Richard F Pops (Director) and William H Rastetter (Director)

Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

About Neurocrine Biosciences

Neurocrine Biosciences logoNeurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Read More 
 
 

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him